Risk of myocardial infarction and death in patients with atrial fibrillation treated with dabigatran or vitamin K antagonists: Meta-analysis of observational analyses

Thrombosis and Haemostasis

Volumn 116, Issue 6, 2016, Pages 1150-1158

  Darwiche, Walid ^a   Bejan Angoulvant, Theodora ^a   Angoulvant, Denis ^a   Babuty, Dominique ^a   Fauchier, Laurent ^a  

^a SERVICE DE DERMATOLOGIE   (France)

Author keywords

Atrial fibrillation; Dabigatran; Myocardial infarction; Vitamin K antagonist

Indexed keywords

ANTIVITAMIN K; DABIGATRAN; ANTICOAGULANT AGENT; VITAMIN K GROUP;

ARTICLE; ATRIAL FIBRILLATION; COHORT ANALYSIS; DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY RATE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RISK FACTOR; ANTAGONISTS AND INHIBITORS; COMPLICATION; MORTALITY; RISK ASSESSMENT;

ANTICOAGULANTS; ATRIAL FIBRILLATION; DABIGATRAN; HUMANS; MYOCARDIAL INFARCTION; OBSERVATIONAL STUDIES AS TOPIC; RISK ASSESSMENT; VITAMIN K;

EID: 85004125650     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH16-06-0483     Document Type: Article

References (34)

1. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-962.
2. Davidson BL. The association of direct thrombin inhibitor anticoagulants with cardiac thromboses. Chest 2015; 147: 21-24.
3. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
4. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013; 368: 1272-1274.
5. Sørensen R, Gislason G, Torp-Pedersen C, et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open 2013; 3.
6. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. J Am Med Assoc 2000; 283: 2008-2012.
7. Wells GA, Shea B, O’Connell D, et al. Newcastle-Ottawa Scale. Available at: http://www.lrica.programsceuoxford.htm
8. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
9. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
10. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in metaanalyses. Br Med J 2003; 327: 557-560.
11. Larsen TB, Rasmussen LH, Skjøth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in ‘real-world’ patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013; 61: 2264-2273.
12. Larsen TB, Rasmussen LH, Gorst-Rasmussen A, et al. Myocardial ischemic events in ‘real world’ patients with atrial fibrillation treated with dabigatran or warfarin. Am J Med 2014; 127: 329-336.e4.
13. Larsen TB, Skjøth F, Nielsen PB, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Br Med J 2016; 353: i3189.
14. Vaughan Sarrazin MS, Jones M, Mazur A, et al. Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. Am J Med 2014; 127: 1179-1185.
15. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015; 131: 157-164.
16. Bouillon K, Bertrand M, Maura G, et al. Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study. Lancet Haematol 2015; 2: e150-159.
17. Lauffenburger JC, Farley JF, Gehi AK, et al. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc 2015; 4: e001798.
18. Villines TC, Schnee J, Fraeman K, et al. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost 2015; 114: 1290-1298.
19. Avgil Tsadok M, Jackevicius CA, Rahme E, et al. Sex Differences in Dabigatran Use, Safety, And Effectiveness In a Population-Based Cohort of Patients With Atrial Fibrillation. Circ Cardiovasc Qual Outcomes 2015; 8: 593-599.
20. Seeger JD, Bykov K, Bartels DB, et al. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost 2015; 114: 1277-1289.
21. Ezekowitz MD, Wallentin L, Connolly SJ, et al. Dabigatran and Warfarin in Vitamin K Antagonist-Naive and -Experienced Cohorts With Atrial Fibrillation. Circulation 2010; 122: 2246-2253.
22. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172: 397-402.
23. Hohnloser SH, Oldgren J, Yang S, et al. Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial. Circulation 2012; 125: 669-676.
24. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. J Am Med Assoc 1999; 282: 2058-2067.
25. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17: 1467-1507.
26. Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, doubleblind, phase II trial. Eur Heart J 2011; 32: 2781-2789.
27. Artang R, Rome E, Nielsen JD, et al. Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. Am J Cardiol 2013; 112: 1973-1979.
28. Lip GYH, Lane DA. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? Am J Med 2010; 123: 785-789.
29. Hohnloser SH, Lip GYH. Dabigatran and myocardial infarction. Chest 2015; 147: e70-71.
30. Frère C, Laine M, Paganelli F, et al. Antiplatelet properties of oral anticoagulants. Int J Cardiol 2015; 181: 413-414.
31. Lip GYH, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014; 35: 3155-3179.
32. Erkens PMG, ten Cate H, Büller HR, et al. Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis. PloS One 2012; 7: e42269.
33. Dickersin K, Chan S, Chalmers TC, et al. Publication bias and clinical trials. Control Clin Trials 1987; 8: 343-353.
34. Pastori D, Pignatelli P, Saliola M, et al. Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation. Int J Cardiol 2015; 201: 513-516.